Breaking News

Lonza, BioWa Ink License Pact with Pfizer

July 30, 2013

Will use POTELLIGENT CHOK1SV cell line

BioWa, Inc. and Lonza have entered into a research agreement with Pfizer for the use of their POTELLIGENT CHOK1SV cell line in the R&D of multiple antibodies in Pfizer’s pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT technology with Lonza’s GS Gene Expression System, which includes the host cell line, CHOK1SV.
 
“We are pleased that the core value of POTELLIGENT Technology has been recognized by a global pharmaceutical company such as Pfizer, and are excited to work together with Pfizer on their innovative antibody research pipelines.” said Yasunori Yamaguchi, Ph.D., president and chief executive officer of BioWa.
 
“The GS System and the CHOK1SV Cell Line continue to be a gold standard for therapeutic antibody development.  We are proud to be able to support Pfizer with this technology for their ongoing development portfolio.” said Karen Fallen, vice president, head of licensing, Lonza Custom Development Services.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016